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Hepatitis B in the United States
Hepatitis B virus (HBV) is a bloodborne virus
that causes both acute and chronic liver dis-
ease.  Viremia can last for several months in
acute infections, and for many years in chron-
ic infections.  Because of crowding and high-
risk behaviors that take place within many jails
and prisons, the transmission of HBV
becomes a serious issue. The following article
will outline HBV in corrections, HBV transmis-
sion, the clinical course of HBV, and vaccine
possibilities.
An estimated 1.25 million, or 5% of the United
States population has serologic evidence of
past or present HBV, and 0.4% - 0.5% have
chronic infection.1 Chronic HBV infection
accounts for 5%-10% of cases of chronic liver
disease and cirrhosis in the United States, and
acute HBV continues to affect approximately
8,000 people each year,2 despite the fact that
a safe and effective HBV vaccine has been
available for more than two decades.
The incidence of acute HBV infection has been
decreasing steadily since the Centers for
Disease Control and Prevention (CDC) and
the Advisory Committee on Immunization
Practices (ACIP) began recommending univer-
sal childhood vaccination and vaccination of
high-risk groups more than a decade ago.3
Partially as a result of this aggressive vaccina-
tion policy, the incidence of acute HBV infec-
tion in 2002 was reported to be 2.8 per
100,000 population, down from a rate of 8.5
per 100,000 in 1990. However, after more than
10 years of decline, the incidence of HBV
among men over age 19 and women aged 40
or older has increased. The most common risk
factors reported among adults with acute HBV
continue to be multiple sexual partners, men
having sex with men, and injection drug use.2
Hepatitis B in Corrections
The high prevalence of markers for HBV infec-
tion among incoming inmates to prisons and
jails was described as early as 1978.4 Since
then, there has been an explosion of the incar-
cerated population in the United States, partic-
ularly in the last two decades, fueled largely by
tougher penalties for drug offenses. The num-
ber of people incarcerated in state or federal
prisons whose most serious crime was a drug
offense has increased 13-fold, from 23,749 in
1980 to 324,601 in 2001.5 Due to this increase
in drug user incarceration, the prevalence of
blood-borne infections in those who are incar-
cerated also increased. Despite the emer-
gence of a HBV vaccine, seroprevalence stud-
ies among inmates have continued to docu-
ment high rates of HBV markers - 30% in
Tennessee,6 35% in Virginia,7 43% in Suffolk
County, Massachusetts,8 and most recently,
20% in Rhode Island.9 It should be noted that
approximately 95% of these cases have
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IDCR MISSION STATEMENT
We changed our name from HEPP Report to IDCR (Infectious Diseases in Corrections Report)
to encompass all infectious diseases that impact the correctional setting. IDCR's goal is to edu-
cate correctional health care providers about the appropriate medical management of prison-
ers infected with HIV, hepatitis, TB, and other infectious diseases; to encourage these
providers to improve their networks with correctional, academic or community-based infectious
disease experts; and to promote a level of infectious disease care in correctional facilities that
is equivalent to the "community standard." 
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resolved infection, and only 5% would be
expected to have chronic HBV.
Additionally, 30% of persons with acute
HBV infection in the United States report
having been in prison or jail at some
point.10
Several recent publications have high-
lighted the transmission of HBV within
prison walls.  In 2001, the CDC reported
on an HBV outbreak in a state correction-
al facility; 11 inmates living in four sepa-
rate dormitories were identified with acute
HBV, for an overall infection rate of 1.2%
among inmates in the facility.  Most of the
infected inmates were asymptomatic.11 A
serosurvey conducted from 1999-2002
among inmates of Georgia's correctional
system identified 92 cases of acute HBV
infection. While it is not know how many of
these 92 cases were acquired in prison,
what is known is that of 57 acute HBV
cases reported between January 2001
and June 2002, 72%, or 41 cases, were
acquired in prison.12 A study in the RI
Department of Corrections identified a
HBV incidence of 2.7 per 100 person-
years among 446 continuously incarcerat-
ed inmates.9
Transmission
HBV is bloodborne and sexually transmit-
ted. The virus is found in moderate to high
concentrations in blood, serum, wound
exudates, semen, vaginal secretions, and
saliva, and is transmitted by percutaneous
or mucosal exposure to these fluids.13
In correctional settings, a disproportion-
ately high prevalence of chronic HBV
infection among inmates provides a reser-
voir for infection of susceptible inmates.
Given the lack of access to condoms (only
two state and five municipal correctional
systems make condoms available to adult
inmates for use in their facilities), sexual
contact between inmates is a major risk
factor for intra-prison transmission; the
CDC reports that 2%-30% of inmates
have sex while incarcerated.14
Similarly, lack of access to needle
exchange (or, indeed, needles) makes
drug use behind bars especially risky,
even if it occurs less frequently than in the
community. A recent survey of injection
drug users in Los Angeles County found
that 15% of 197 participants released
from detention in the previous year report-
ed having injected drugs while incarcerat-
ed, and that 79% of those who had ever
injected while incarcerated reported shar-
ing needles.15
Other HBV transmission risks in the cor-
rectional setting include: fights, bites,
cuts, injuries, sharing razors, tattooing
and piercing.16
Clinical Course and Natural History
The incubation period of HBV ranges from
45-160 days. Acute HBV infection is
asymptomatic in 50% of adults. When
clinical manifestations do occur, they usu-
ally correspond with the following phases:
preicteric (lasting three to 10 days, char-
acterized by malaise, anorexia, nausea,
vomiting, right upper quadrant abdominal
pain, fever, headache, myalgias, skin
rashes, arthralgias and arthritis, and dark
urine), icteric (lasting one to three weeks,
characterized by jaundice, light or grey
stools, hepatic tenderness and
hepatomegaly), and convalescence (other
symptoms disappear but fatigue or
malaise may persist for up to several
months).17
Fulminant hepatitis is rare, occurring in
1%-2% of newly infected persons, but its
mortality rates are high, ranging from 63%
to 93%.  Between 200 to 300 people in the
United States die each year of HBV-
induced fulminant hepatitis.17
Most adults with acute HBV recover com-
pletely, with elimination of HBV surface
ntigen (HBsAg) from the blood and pro-
duction of antibody to the surface antigen
(anti-HBs), creating immunity from future
infection. However, up to 10% of adults
with acute infection develop chronic HBV
infection. Most of the serious complica-
tions associated with HBV are the result of
chronic infection.
The majority of adults with chronic HBV
are asymptomatic, though they are capa-
ble of infecting others.  One third of chron-
ically infected persons have no evidence
of liver disease.  In the other two thirds of
those with chronic HBV infection, long
term effects on infection include chronic
hepatitis, cirrhosis, liver failure, and hepa-
tocellular carcinoma (HCC).  An estimated
3,000 to 4,000 persons in the United
States die each year from HBV-related
cirrhosis, and approximately 1,000 to
1,500 die from HBV-related HCC.
Persons with chronic HBV infection are up
to 300 times more likely to develop HCC
than persons without HBV infection.17
There is some interest lately in occult
HBV, defined as the demonstration of anti-
bodies to the HBV core antigen (anti-
HBc), without either HBsAg or anti-Hbs,
with or without the presence of low-level
circulating virus.16 Cohorts of persons with
HIV, hepatitis C virus (HCV), and
HIV/HCV coinfection have all been found
to have a higher prevalence of occult HBV
infection than previously expected when
tested for HBV with ultra-sensitive
assays.18 However, the clinical signifi-
cance and transmissibility of HBV DNA in
patients with occult HBV infection is a
matter of some debate.19
Hepatitis B vaccine
The first vaccine against HBV, a plasma-
derived vaccine, was introduced in 1981.
This vaccine was thought to be safe and
was effective, but not well accepted due to
the use of thimerosal, an ethyl mercury-
containing preservative used in the drug,
and was removed from the market in
1992. The vaccine that is currently
licensed and used widely is a recombinant
HBV vaccine, first licensed in 1986 and
produced by Merck and Company
(Recombivax HB) and SmithKline
Beecham (Energix-B).  Vaccines made by
the two manufacturers both induce the
same immunity against HBV. Twinrix, a
combined hepatitis A and B virus vaccine
manufactured by GlaxoSmithKline
Biologicals, was licensed in 2001.20
After 3 intramuscular doses of HBV vac-
cine, over 90% of healthy adults develop
adequate antibody responses. Larger
vaccine doses or an increased number of
doses are often required to induce an anti-
body response in hemodialysis patients
and may be necessary in immunocompro-
mised patients.  Vaccine-induced immuni-
ty levels decline with time, but immune
memory remains intact for at least 13
years following immunization, and adults
with declining antibody levels are still pro-
tected from clinically significant HBV
infection. Therefore, for adults with normal
immune status, neither booster doses nor
routine serologic testing to assess
immune status are indicated.20 The stan-
dard HBV vaccination schedule consists
of the second and third doses being
administered 1 and 6 months after the
first.21
The first official recommendations for the
use of the HBV vaccine, published in
1982, included a recommendation to vac-
cinate "inmates of long-term correctional
facilities".21 However, difficulty providing
the vaccine to some populations, such as
men who have sex with men and injection
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After more than 10 years 
of decline, incidence 
of HBV among 
men over age 19 and 
women aged 40 or older 
has increased.
3drug users, led to the assumption in the
late 1980s and early 1990s that high-risk
adults could not be vaccinated before
exposure to the virus, even by "aggressive
vaccination programs."22 Therefore, priori-
ty was given to universal childhood vacci-
nation as a national policy over targeted
vaccination of high-risk adults.3
Throughout the evolution of the national
vaccination policy, the CDC has continued
to recommend vaccination of adults in cor-
rectional facilities.14 In a survey published
in 2001, the only states to routinely offer
HBV vaccine to inmates included
Michigan and Texas.23 Texas has since
discontinued its program due to a lack of
funds.12 However, Texas continues to rou-
tinely administer HBV vaccine to HIV+
inmates who are seronegative for HBV.
Between 2002-2003, Indiana initiated a
program in which HBV vaccination was
offered to all incoming inmates. Nearly
100% of inmates participated, many
receiving three shots before release.
Unfortunately, this program has also
ended, due to lack of funds.  Other states
have since initiated vaccination programs
for adult inmates.24 However, the practice
remains rare and the exact number of
states currently offering routine HBV vac-
cination to inmates is difficult to ascertain.
While HBV vaccination for those who are
incarcerated presents a cost to correction-
al systems, the intervention overall is a
cost savings since net savings accrue to
the entire health care system.
Nonetheless, the vaccinations have been
a difficult "sell" to correctional health care
officials with ever-restrictive budgetary
concerns. Because prisons and jails
acquire a substantial portion of the popu-
lation at risk for HBV infection and often
offer a first-time opportunity for medical
care, the opportunity that prisons and jails
have for an effective health intervention to
prevent HBV infection is substantial.25
Several pilot programs have demonstrat-
d the feasibility of implementing such a
program in the correctional setting. In a
pilot program in the Women's Division of
Rhode Island State Prison, 65% of those
offered HBV vaccine accepted at least
one dose.26 The program has since been
expanded to include the Men's Division;
cceptance rates there have been
upwards of 90% (unpublished data).
From 2000 to 2002, the Texas Department
of Criminal Justice offered HBV vaccine to
all of its estimated 40,000 entering
inmates, with acceptance rates of 85% in
jail and 72% in prison.  
Though the length of stay for many incar-
cerated persons is not long enough to
complete the three-dose HBV vaccine
series (this is especially true for jail facili-
ties where up to one half are released
within 24-48 hours27), a single dose offers
immunity in up to 55% of those vaccinat-
ed, and two doses offers immunity in up to
85%.28 Alternative vaccination schedules
can speed the process and allow inmates
who are only incarcerated for a short time
to complete the series. An alternative
schedule that can be used for vaccination
is zero, two, and four months. In this short-
ened series, the third dose needs to be
given two months after the second dose
nd four months after the first dose. Given
the high rate of recidivism in prisons and
jails and the fact that one need not restart
an HBV vaccine series if the interval
between doses is longer than recom-
mended, inmates who are re-entering
prison or jail after being released may
restart a series where they left off at their
last incarceration.17
Conclusion
Though the United States has made sub-
stantial progress towards eliminating HBV
with universal childhood vaccination, an
opportunity to prevent 30% of new HBV
cases is missed each year in the correc-
tional setting. Though most adults infected
with HBV recover, acute HBV can cause
substantial morbidity, and chronic infec-
tion can cause chronic hepatitis, cirrhosis,
HCC, and death. Education of correction-
al personnel, as well as providing vac-
cines to personnel, may encourage vacci-
nation programs of inmates. Routine HBV
vaccination of inmates is in the best
interest of the health of prisoners and the
public.
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Dear Correctional Colleagues:
All of us working in correctional public health are familiar with the horrendous costs associated
with the treatment of preventable diseases.  Our patients come to us from the free commu ity
with a lifetime of neglected or undiagnosed medical problems: HIV, HCV, HBV, gonorrhea,
chlamydia, syphilis, mental illness, diabetes, hypertension, hyperlipidemia…. Once they step
through our gates, they finally achieve something that all Americans deserve but many do not
have - a constitutional right to a minimum standard of health care.  
Not surprisingly, many correctional systems are running chronic budgetary deficits as they
struggle to cover the rising costs associated with diagnosis and treatment of chronic medical
problems. The irony is that more affordable approaches exist that could be implemented to
address many of these societal problems. For over 20 years, a safe, effective vaccine has
been available that can in a cost-effective manner decrease the burden of HBV and associat-
ed chronic liver disease. However, not all children are vaccinated for HBV, and an alarming
number of at-risk individuals eventually end up as wards of our correctional system. Most of
the life-time costs associated with chronic liver disease will not fall upon jails and prisons, but
rather upon society after inmates are released.  As a result, many systems that struggle to
provide treatment for other medical conditions have not intensively invested in vaccination
programs for at-risk inmates.  The opportunity is therefore lost; the potential savings to society
are squandered.
As my colleagues in correctional medicine have before me, I again call for the establishment
of a Vaccines for At-risk Adultsprogram. By making free or deeply discounted vaccines avail-
able for all at-risk adults, including those who are incarcerated, we can turn a correctional
challenge into a public health opportunity. Only by working together with our free-world col-
leagues can we formulate an effective societal response to the medical needs of those who
have been temporarily entrusted to our care. 
This month, Drs. Rich and Schwartzapfel provide an excellent review of hepatitis B in correc-
tions. Drs. Dieterich, Aftab, and Martin discuss HBV treatment options and we also reprint
algorithms for the diagnosis and treatment of those with chronic hepatitis B. At the conclusion
of this issue, readers will have a better understanding of the prevention, epidemiology, natural
history, and treatment of hepatitis B. We hope that you find this issue useful, and we look for-
ward to seeing you at our annual preconference infectious diseases seminar, to be held on
Saturday, November 13, 2004 in conjunction with the fall meeting of the National Commission
on Correctional Health Care in New Orleans.  
Sincerely,
Joseph Bick, MD
LETTER FROM THE EDITOR
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5HEPATITIS B MANAGEMENT ALGORITHMS
SCREENING LABS
Initial screening:HBsAg, anti-HBc (lgG and lgM), anti-HBs
All HBsAg+ subjects:HBeAg, anti-HBe, quantitative HBV DNA level by PCR
HBeAg Negative
(precore and core promoter mutations)
Quantitative HBV DNA by PCR
HBV DNA 10
Normal ALT
Biopsy, treat if disease
Elevated ALT
Treatment with IFN, 
LAM or ADV*
Consider ADV/LAM 
combination therapy and
longer duration
*Preferred 
(low rate of resistance)
OTHER CONSIDERATIONS
Hepatocellular Carcinoma (HCC):Screen high risk 
populations, i.e. men >45 years, patients with cirrhosis or 
family history of HCC, every 6 months with AFP and liver
imaging (ultrasound, CT or MRI).
Inactive Carriers:ALT and quantitative HBV DNA by PCR
every 3 to 6 months and exclude other causes of disease.
Screen for HCC in relevant populations.
No treatment 
Monitor ALT
every 6 to 12 months
Reprinted from Hepatitis B Resource Network www.h-r-n.org
HBsAg + - - + + +
Anti-HBs - + + - - -
HBeAg + - - + - -
Anti-HBe - +/- - - + +
Anti-HBc lgG + + - + + +
Anti-HBc lgM + - - - - -
HBV DNA (PCR) + - - + + -
ACUTE
HBV
INFECTION
PAST
EXPOSURE
(IMMUNITY)
VACCINE
RESPONDER
CHRONIC
HBV
INFECTION
CHRONIC
PRECORE
MUTANT
INACTIVE
CARRIER
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TREATMENT OF PATIENTS WITH CIRRHOSIS
In conjunction with a Liver Specialist
Compensated Cirrhosis
TREATMENT OF E ANTIGEN NEGATIVE PATIENTS
Quantitative HBV DNA by PCR
Treat with ADV* or LAM 
Consider ADV/LAM 
combination therapy
*Preferred 
(low rate of resistance)
Observe or treat
with ADV or LAM 
Consider ADV/LAM
combination therapy
Decompensated Cirrhosis
HBV DNA Detectable by Quantitative PCR?
Treat with ADV or LAM 
Waitlist for transplant
Observe 
Waitlist for transplant
6SPOTLIGHT: HEPATITIS B VIRUS (HBV)/HIV CO-INFECTION AND TREATMENT OPTIONS
Aftab Ala,* MD, Advanced Liver Fellow, Division of Liver Diseases, Mount Sinai School of Medicine, New York, NY, 10029
Douglas Dieterich,** MD, Vice Chair and Chief Medical Officer Department of Medicine, The Mount Sinai Medical Centre, One Gustave L. Levy Place,
New York, NY 10029-6574
HIV AND HBV CO-INFECTION
Up to 96% of HIV-infected people have been co-infected with HBV.1,2
In the 15 years after its emergence, HIV-associated mortality was so
high that treating HBV infection did not appear to be a priority.
Fortunately, with the development of successful highly active anti-
retroviral therapy (HAART), individuals with HIV infection now have
a better prognosis with a steady decline in the number of new cases
of HBV infection over the last 10 years.3 Aggressive treatment of
HBV in co-infected patients will hopefully lead to improved tolerabil-
ity of antiretroviral therapy and decreased morbidity and mortality. 
The goal of therapy for hepatitis B includes prevention of cirrhosis
and other consequences of chronic liver disease. Therapy for HIV-
HBV co-infected patients needs to be individualized. The liver-relat-
ed mortality in HIV-HBV co-infected patients is 14-fold higher than
that for either virus alone4 and HIV-positive patients are 3 to 6 times
more likely to develop chronic hepatitis B following occult infections
rather than HIV-negative patients. HIV-HBV co-infection is associat-
ed with a higher rate of cirrhosis than HBV infection alone.  In co-
infected individuals HBV DNA and HBeAg levels tend to be higher;
ALT and AST levels are lower; and there is a lower rate of sponta-
neous HBeAg seroconversion.5 Co-infected patients have accelerat-
ed histologic progression of liver disease, although there are con-
flicting data on the impact of HBV on HIV infection.6 While some
studies have shown an increased rate of HIV progression to AIDS
among individuals with markers of exposure to HBV (anti-HBc), oth-
ers have not shown any change in the progression of HIV disease or
survival.7,8,9,10
CHRONIC HEPATITIS B THERAPY
The overall aim of management of chronic HBV is to prevent pro-
gression of liver disease to cirrhosis and HCC. Since HBV replica-
tion is important, effective therapy should suppress HBV DNA to the
lowest levels possible. Molecular assays such as PCR enables the
accurate monitoring of HBV DNA at levels as low as 100-1000
copies/mL and should ideally establish a patient's baseline HBV
DNA prior to treatment, and thus monitor response to antiviral ther-
apy or viral rebound associated with resistance. That is, as therapy
is extended to more HBeAg-negative chronic HBV individuals, the
use of HBV DNA testing will be increasingly incorporated into clini-
cal decision-making.
The threshold level of HBV DNA for determination of candidates for
therapy is >105 copies/mL for patients with HBeAg-positive chronic
hepatitis B.11 Patients should also have elevated ALT levels and/or
evidence of liver injury on liver biopsy. A lower serum HBV DNA
threshold is needed for patients with HBeAg-negative chronic
hepatitis B and those with decompensated cirrhosis. Current guide-
lines recommend thresholds of >104 copies/mL and >103 copies/mL
for these patient groups, respectively. Individuals with serum HBV
DNA of less than 105 are deemed inactive carriers, whereas those
with levels greater than 105 copies/ml have chronic infection with
ongoing viral activity and more potential for progressive liver dis-
ease. HBV levels are used to guide therapy but other factors such
as liver histology are also required. 
Interferon alpha (IFN), lamivudine and adefovir are approved as ini-
tial therapy for chronic hepatitis B, although the advantages and dis-
advantages of the three therapies should influence their selection.  
(i)Combination therapy
Combination therapy, at least theoretically, is likely to be more effec-
tive than monotherapy in suppressing viral replication and may
decrease or delay the emergence of drug resistance. It may be of
particular value in decompensated cirrhosis. Several large studies
are underway exploring the use of two nucleoside/nucleotide antivi-
ral agents or an antiviral plus IFN in compensated patients. 
(ii)Pegylated Interferon
Peginterferon alfa-2a has a long mean half-life of 80 h, sustained
plasma drug concentrations and little peak-to-trough fluctuation.12
The potential for development of viral resistance with  lamivudine
and possibly adefovir is the critical step in allowing for treatment dis-
continuation. In a recent study HBeAg-negative chronic HBV indi-
viduals had significantly higher rates of response, sustained for 24
weeks after the cessation of therapy, with peg interferon alfa-2a (180
µg once weekly) plus lamivudine than with lamivudine alone (100 mg
daily).12 The rates of sustained suppression of HBV DNA to below
400 copies per milliliter were 19 percent with peg interferon alfa-2a
monotherapy, 20 percent with combination therapy, and 7 percent
with lamivudine alone. Loss of hepatitis B surface antigen occurred
in 12 patients in the peginterferon groups, compared with 0 patients
in the group given lamivudine alone.
(iii)Lamivudine and concept of resistance
Selection of resistant HBV during lamivudine treatment is a multifac-
torial process in which the replicative capacity of the virus, host
immune response (reflected by pretreatment ALT values), and the
HBV genotype itself play important roles.13 Thus, different mutation-
al patterns of resistant HBV genotypes A and D may have an impact
on the treatment strategies for lamivudine-resistant HBV.14
In patients with HBV infection alone, resistance ranges from 24% in
the first year of treatment to 66% by year 4; in HIV-HBV-coinfected
patients, resistance is more frequent, with 47% resistant to lamivu-
dine at year 2 and 90% at year 4.15,16,17
(iv)Emtricitabine (FTC)
FTC was approved in July 2003 by the FDA for the treatment of HIV
and appears to be a potential useful drug in the management of HIV-
HBV co-infection.  FTC is a fluorianted nucleoside reverse transcrip-
tase inhibitor, similar to lamivudine, but with a longer half life, that
produces similar suppression of HBV DNA in HIV co-infection as that
observed in patients with HBV alone. What is encouraging is that the
safety profile of FTC in HIV-HBV-coinfected patients was similar to
that observed in patients infected with HBV alone. FTC is well toler-
ated and has potent anti-HIV activity, although due to cross-resis-
tance, it is not indicated after lamivudine failure.18 Previous FTC
studies have shown significant in vitro activity against HBV. This was
confirmed from two controlled randomized clinical trials with different
dose ranges of FTC (25 to 300 mg) which demonstrate a 3.4 log10
reduction of viral HBV load in a total of 147 patients, performed for
the treatment of HIV (n = 52).18,19
(v)Adefovir 
Adefovir (a phosphorylated nucleotide analog of adenosine
monophosphate) acts by inhibiting HBV DNA polymerase, thereby
causing HBV DNA chain termination. Adefovir is indicated in the
treatment of chronic HBV in adults with evidence of active viral repli-
cation and either evidence of elevation of ALT or AST, or histologi-
Continued on page 7
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7cally active disease, and is given orally, once daily, at a dose of
10mg.  Treatment with adefovir has lead to histologic improvement,
as defined by as a decrease in the knodell necroinflamatory score
and HBeAg seroconversion. Significant in the findings during clini-
cal trials of adefovir is the low adefovir-associated HBV resistance;
the incidence of adefovir resistance-associated mutations was 0%
at 48 weeks, 2% at 96 weeks, and 1.8% at 144 weeks.  Adefovir has
demonstrated anti-HBV activity in patients with HBV containing
lamivudine resistance-associated mutations.20
(vi)Tenofovir (TDF)
There is an increasing interest in TDF in the treatment of HBV-HIV
co-infection. The anti-HIV properties of TDF found lacking in ade-
fovir, coupled with its excellent tolerability in advanced HIV infec-
tion, makes TDF more attractive for the patient with limited thera-
peutic options in which the goal of antiretroviral therapy is to lower
the HIV RNA load. Preliminary results demonstrate the anti-HBV
efficacy of TDF (300mg) in HIV-infected patients with lamivudine
resistance after 9 months of antiretroviral therapy.20 Although not
approved by the FDA for the treatment of HBV, TDF has excellent
activity against HBV and many co-infected patients have been treat-
ed with TDF plus lamivudine. It is likely that we will see studies look-
ing at the combination of FTC and TDF in the management of HIV-
HBV-coinfected individuals. Newly emerging data demonstrate the
need for appropriate dosing to avoid renal toxicity of TDF.21 his is
a rare occurrence; however, when this toxicity does occur, it resem-
bles adefovir renal toxicity, which is a Fanconi-like syndrome that is
reversible. 
(vii)Entecavir (ETC)
ETC is a novel guanine analogue which is active against the HBV
DNA polymerase and thus prevents priming, negative strand for-
mation, and positive strand synthesis.22 ETV has been proven to be
effective in patients previously treated with interferon and against
lamivudine-resistant HBV strains.23 These findings must be con-
firmed in the larger, ongoing, worldwide phase 3 studies of ETC in
nucleoside analogue-naïve patients and in lamivudine-refractory
patients.
In conclusion, there have been many changes in the therapies
associated with treatment of hepatitis B and HIV-HBV co-infection.
Ultimately, the goals are to achieve a significant decline in the mor-
bidity and mortality attributed to HBV infection among those infect-
ed with HIV.
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SPOTLIGHT...(continued from page 6)
The 1st Annual Stephen Tabet Prison Medicine Advocacy Award
This award will be given in memoriam of Dr. Stephen Tabet, correctional physician and advocate, who passed away this
past July. The presentation of this award will take place at the NCCHC on Saturday, November 12, 2004 following the
IDCR pre-conference seminar.
The individual presented with this award will have demonstrated selfless commitment to HIV-positive incarcerated per-
sons, and show a continued interest and passion for caring for those with HIV in corrections in the future.
This individual must be dedicated not only to improving prison health care, but must also serve as a mentor to other health
care providers.
This individual must present with a compassion for treating the most challenging, most underprivileged patients.  
Nominations for this award should be sent to idcr@brown.edu by November 6, 2004.
IN MEMORIAM: DR. STEPHEN TABET 1961-2004
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Chest 2004 
October 23 - 28, 2004
Seattle, WA
Call: 847.498.1400
Fax: 800.343.2227 
Visit: www.chestnet.org/CHEST/
program/index.php. 
Practical Management of HIV:
A One Day Regional
Workshop Covering the
Practical Aspects of HIV
Management
October 23, 2004
Orlando, FL
October 25, 2004
Sturbridge, MA 
Call: AAHIVM: 310.278.6380 or
NEAETC: 617.262.5657
Visit: www.aahivm.org or
www.neaetc.org.
44th Annual ICAAC
October 30 - November 2, 2004
Washington, DC
Call: 800.974.3621
Visit: www.asm.org
HIV Mini-fellowship Program
November 8 - 10, 2004
University of Texas Medical
Branch, Galveston, TX
Call: Victoria Korschgen at
409.772.8799 
Email: vikorsch@utmb.edu
National Conference on
Correctional Health Care
November 13 - 17, 2004
New Orleans, LA
Call: 773.880.1460
Visit: www.ncchc.org
Society of Correctional
Physicians:
2004 Annual Conference
Acute & Chronic Issues in
Pain Management & Wound
Care
November 14, 2004
New Orleans, LA
Call: 800.229.7380
Email: scp@corrdocs.org
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DATES
8
Study Shows Hepatitis B Transmission High in
R.I. Prisons
In the first study to gauge the risks of contracting
HIV and hepatitis B virus (HBV) infections in
Rhode Island prisons, Brown University
researchers found that a significant number of men
acquire HBV while incarcerated-a finding that led
the team to call for prison-wide vaccinations. To
conduct the study, blood was analyzed from
mandatory, consensual tests taken when inmates
entered the Adult Correctional Institute in
Cranston, R.I. Researchers gathered test results
on 4,269 men sentenced between 1998 and 2000.
Nearly two percent of incoming inmates tested
positive for HIV. Twenty percent had SEROLOGIC
EVIDENCE OF HBV and 23 percent had serologic
evidence of HCV infection. To determine if trans-
mission of these infections was occurring within
the prison, researchers retested 446 men who
were still incarcerated at least one year later. While
none of the inmates contracted HIV infection, and
less than one percent of inmates contracted HCV,
almost three percent of inmates contracted HBV
infection-a rate higher than indicated in previous
prison research and markedly higher than the
national average. Since the time of the study, rou-
tine vaccination has been expanded to the men's
division of the R.I. Department of Corrections (a
vaccination program was already in place for
women), making the state one of only a few in the
nation that routinely offers hepatitis B vaccinations
to all its inmates.
NATAP - www.natap.org
Roche Seeks Approval for Pegasys Use for
Chronic Hepatitis B 
Roche recently announced the submission of a
new supplemental license application with the U.S.
Food and Drug Administration to market Pegasys®
(peginterferon alfa-2a) for the treatment of chronic
hepatitis B (CHB). Pegasys received FDA approval
for the treatment of chronic hepatitis C in October
2002. Roche submitted this filing based on
Pegasys data from its comprehensive clinical
development program in hepatitis B. This program
involved more than 1,500 patients with chronic
hepatitis B infection from three separate studies.
One phase II study compared Pegasys to standard
interferon in patients with HBeAg-positive disease.
Two phase III studies compared Pegasys to Epivir-
HBV® (lamivudine) in patients with HBeAg-posi-
tive disease and in patients with HBeAg-negative
disease (a more difficult to treat mutation of the
hepatitis B virus), respectively.  Researchers found
that peginterferon alfa-2a alone or in combination
with lamivudine resulted in higher rates of sus-
tained response (19% and 20%, respectively)
among patients with HBeAg-negative chronic
hepatitis B than did lamivudine monotherapy (7%).
The two studies are the largest trials conducted to
date in the patient populations infected with either
variation of hepatitis B.
NATAP - www.natap.org
New England Journal of Medicine
New Nucleoside Analogue Against HBV: New
Answers, New Questions
In a phase II dose finding study of clevudine (L-
FMAU), a new pyrimidine nucleoside analogue, 32
patients were treated with 10, 50, 100, or 200 mg
levudine once daily for 28 days. A profound -2.5
to -3.0 log10 reduction of hepatitis B virus (HBV)
DNA was observed at all doses. Viral suppression
was associated with a transient alanine amino-
transferase increase in some patients, particularly
t the 100 mg dose.  Suppression was unusually
prolonged in most patients (-1.2 to -2.7 log10 at six
months post-dosing) and resulted in HBe antigen
l s  and anti-HBe seroconversion in an unexpect-
edly high number of six and three out of 27
patients, respectively. The mechanisms of activity
for this medicine remain unclear. Study authors
question whether it is possible that this particular
nucleoside analogue may have immunomodulato-
ry or other additional effects, as well as the etiolo-
gy of the transient alanine aminotransferase
increases observed in some patients. 
Marcellin et al. HEPATOLOGY. 2004;40:140-148.
NATAP - www.natap.org
Study: Tenofovir Disoproxil Fumarate Effective
in Patients Coinfected with HIV/ HBV
Coinfection with HIV-1 increases the risk of HBV-
associated progressive liver disease. Among indi-
viduals coinfected with HIV and HBV in two phase
III randomized controlled trials, therapy with teno-
fovir DF has clearly demonstrated anti-HBV viro-
l gic efficacy. During 48 weeks of therapy with
tenofovir DF, a mean reduction of 4 - 5 log10
copies/mL in the HBV DNA level was seen in anti-
retroviral therapy-experienced HIV-HBV-coinfect-
ed individuals with or without resistance to lamivu-
dine. A similar reduction in the HBV DNA level was
seen in antiretroviral therapy-naive HIV-HBV-coin-
fected individuals who received combination thera-
py with lamivudine and tenofovir DF as a compo-
nent of their initial three-drug HAART regimen. 
Gregory J. Dore et al. Jour Inf Dis. 2004;189:1185-
1192
NATAP - www.natap.org
IN THE NEWS
RESOURCES
The CDC's website on Viral Hepatitis B
www.cdc.gov/ncidod/diseases/hepatitis/b/
index.htm
Hepatitis B Foundation
www.hepb.org
MedlinePlus: Hepatitis B
www.nlm.nih.gov/medlineplus/hepatitisb.html
Oct./Nov. 2004     Vol. 7, Issues 10&11visit IDCR online at www.IDCRonline.org
SELF-ASSESSMENT TEST FOR CONTINUING MEDICAL EDUCATION CREDIT
Brown Medical School designates this educational activity for 1 hour in category 1 credit toward the AMA Physician’s Recognition Award.
To be eligible for CME credit, answer the questions below by circling the letter next to the correct answer to each of the questions. 
A minimum of 70% of the questions must be answered correctly. This activity is eligible for CME credit through April 30, 2005. 
The estimated time for completion of this activity is one hour and there is no fee for participation.
1. Correctional systems that have offered HBV vaccine to
inmates have:
a) Experienced an increase in HBV infection among inmates
b) Experienced high percentages of participation by inmates
c) Lost funding and have had to discontinue vaccination 
programs
d) b and c
e) All of the above
2. Seroprevalence studies among inmates have continued to
document low rates of HBV markers.  True or False.
a) True
b) False
3. The HBV vaccine was/is:
a) First introduced in 1981
b) Recommended by the CDC to all adults in correctional 
facilities
c) Given at zero, one, six months, or alternatively, at zero, 
two, four months
d) All of the above
4.  According to a recent study of injection drug users, the per-
centage of previously incarcerated persons who injected drugs
while incarcerated, is closest to:
a) 0
b) 20
c) 40
d) 80
5. All of the following statements are true except:
a) HBV is found in blood, semen, and saliva.
b) Fulminant hepatitis occurs in approximately 63%-93% of 
newly infected persons.
c) HBV vaccine consists of three intramuscular doses.
d) Two doses of HBV vaccine offers immunity in up to 85% 
of those vaccinated.
6. The majority of adults with chronic HBV are asymptomatic and
are not capable of infecting others.  True or False.
a) True
b) False
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